SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers”, in Drug Discovery Today. The publication’s lead author is Dr. George Warren, Principal Scientist at ...